| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
IC50: 0.15 µM (Cdc25A); 0.19 µM (Cdc25B); 0.06 µM (Cdc25C)[1]
M5N36 targets the Cdc25 family of dual-specificity phosphatases, including Cdc25A, Cdc25B, and Cdc25C. The compound demonstrates potent inhibitory activity against all three isoforms, with IC50 values of 0.15 µM for Cdc25A, 0.19 µM for Cdc25B, and 0.06 µM for Cdc25C. This selectivity profile, with greatest potency against Cdc25C, allows for targeted inhibition of the G2/M checkpoint. By inhibiting Cdc25 phosphatases, M5N36 prevents CDK activation and induces cell cycle arrest. |
|---|---|
| ln Vitro |
In MDA-MB-231 cells, M5N36 (5, 10 µM; 24 h) promotes p-CDK1 and p-CDK2 expression [1].
In vitro, M5N36 demonstrates potent anti-proliferative activity against multiple cancer cell lines. The compound increases the expression of phosphorylated CDK1 (p-CDK1) and phosphorylated CDK2 (p-CDK2), consistent with inhibition of Cdc25 phosphatase activity and cell cycle arrest. M5N36 shows concentration-dependent inhibition of Cdc25 activity in biochemical assays and cellular models. The compound's anti-proliferative effects are observed in various cancer cell types, supporting its potential as an anticancer research tool. |
| ln Vivo |
In vivo activity data for M5N36 are limited, as the compound is primarily studied in vitro. Based on its mechanism of Cdc25 inhibition and anti-proliferative activity, the compound is expected to inhibit tumor growth in animal models by inducing cell cycle arrest in cancer cells. However, detailed efficacy studies in animal models have not been extensively reported. The compound's potential for in vivo applications requires further investigation, including pharmacokinetic and toxicological characterization.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for M5N36 typically involves measuring the activity of recombinant human Cdc25A, Cdc25B, or Cdc25C phosphatases using a fluorogenic substrate such as 3-O-methylfluorescein phosphate (OMFP). Purified enzyme is incubated with varying concentrations of M5N36 (0.001-100 µM) in assay buffer at 37°C for 10-30 minutes. The reaction is initiated by adding the substrate, and fluorescence is measured continuously. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: Eca-109, HepG2, MCF-TAM, MDA-MB-231, Raji, SGC-7901, SW-620, HUVEC cells Tested Concentrations: Incubation Duration: Experimental Results: demonstrated anti-proliferative activity with IC50s of 2.88, 3.57, 10.00, 2.00, 1.20, 6.03, 3.39, 2.40 µM for Eca-109, HepG2, MCF-TAM, MDA-MB-231, Raji, SGC-7901, SW-620, HUVEC cells, respectively. Western Blot Analysis[1] Cell Types: MDA-MB-231 cells Tested Concentrations: 5, 10 µM Incubation Duration: 24 h Experimental Results: Increased the expression of Cdc25A, Cdc25B, increased the expression of p-CDK1 and p-CDK2. For in vitro cell-based assays, cancer cell lines such as HeLa, MCF-7, or HCT116 are cultured in appropriate medium and treated with M5N36 at concentrations ranging from 0.1-100 µM for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. Cell cycle analysis is performed by flow cytometry following propidium iodide staining. Cdc25 activity is measured in cell lysates using a phosphatase activity assay. p-CDK1 and p-CDK2 expression is assessed by Western blot. |
| Animal Protocol |
In vivo animal studies for M5N36 have not been extensively reported. Based on the compound's mechanism as a Cdc25 inhibitor, potential in vivo studies would involve administration to tumor-bearing mouse models via oral gavage, intraperitoneal injection, or intravenous injection at doses ranging from 1-50 mg/kg. Tumor growth would be monitored by caliper measurements. Cell cycle markers and Cdc25 activity would be assessed in tumor tissues by immunohistochemistry and Western blot.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of M5N36 have not been fully characterized. Molecular formula is C₂₀H₁₆ClN₅O₃. CAS number is 2832887-40-6. Detailed pharmacokinetic parameters such as bioavailability, half-life, and protein binding have not been reported. Stability in solution may be limited and fresh solutions should be prepared for each experiment. The compound should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
Toxicology data for M5N36 are limited. As a research compound, it has not been systematically evaluated for safety. The compound's mechanism of cell cycle inhibition suggests potential cytotoxicity, which may be desirable for anticancer applications but requires careful safety assessment. Standard toxicological endpoints including cell viability, genotoxicity, and organ toxicity should be evaluated. The compound is intended for research use only and is not approved for human use.
|
| References | |
| Additional Infomation |
M5N36 is a potent and selective inhibitor of Cdc25 phosphatases, with IC50 values of 0.15 µM (Cdc25A), 0.19 µM (Cdc25B), and 0.06 µM (Cdc25C). The compound shows greatest potency against Cdc25C and exhibits anti-proliferative activity in cancer cell lines. M5N36 increases p-CDK1 and p-CDK2 expression, consistent with Cdc25 inhibition and cell cycle arrest. It is a valuable research tool for studying cell cycle regulation and cancer biology, intended for research use only.
|
| Molecular Formula |
C20H16CLN5O3
|
|---|---|
| Molecular Weight |
409.825742721558
|
| Exact Mass |
409.094
|
| CAS # |
2832887-40-6
|
| Related CAS # |
M2N12;2376577-06-7
|
| PubChem CID |
166642624
|
| Appearance |
Orange to red solid powder
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
679
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1C2=C(C(=O)C(Cl)=C(NC(C3=CN(C4=CC=C(CO)C=C4)N=N3)C)C2=O)C=CC=1
|
| InChi Key |
XSEYUBHGRYYOGZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16ClN5O3/c1-11(15-9-26(25-24-15)13-6-4-12(10-27)5-7-13)23-18-16(21)19(28)14-3-2-8-22-17(14)20(18)29/h2-9,11,23,27H,10H2,1H3
|
| Chemical Name |
6-chloro-7-[1-[1-[4-(hydroxymethyl)phenyl]triazol-4-yl]ethylamino]quinoline-5,8-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4400 mL | 12.2002 mL | 24.4004 mL | |
| 5 mM | 0.4880 mL | 2.4400 mL | 4.8801 mL | |
| 10 mM | 0.2440 mL | 1.2200 mL | 2.4400 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
